We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERICS ENTER METFORMIN ER MARKET IN SECOND EXCLUSIVITY
GENERICS ENTER METFORMIN ER MARKET IN SECOND EXCLUSIVITY
June 29, 2004
Multiple generic firms have launched versions of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucophage XR, 500-mg strength tablets, under a “second tier” of 180-day marketing exclusivity.